EKF Diagnostics Investor Announcements


EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

EKF Diagnostics Holdings plc announces that a general meeting of the Company will be held on 19 October 2018.

19th Sep 2018

EKF Diagnostics Holdings plc announces its unaudited interim results for the six months ended 30 June 2018. 

17th Sep 2018

EKF Diagnostics Holdings plc  announces that it will release its interim results for the six months ended 30 June 2018 on Wednesday 19 September 2018.

EKF to undertake further market soundings ahead of a prospective equity Fundraising by Renalytix AI and the admission of its shares to trading on AIM.

Standard form for notification of major holdings. 

9th Aug 2018

EKF Diagnostics provides shareholders with the following update on current trading. 

EKF announces that it has signed a private label distribution agreement with McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation – the Fortune Global 500 healthcare distribution specialist and one of the largest companies in the US by revenue – for the Company’s hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm.

Standard form for notification of major holdings. 

EKF Diagnostics announces exclusive distribution agreement with Asahi Kasei Pharma to market Lucica® Glycated Albumin-L. 

EKF Diagnostics announces an exclusive manufacturing agreement with Oragenics, Inc. in the United States.